HIPPoS

Short title: A study of GDC-0449 medication given before surgery to patients with Pancreatic Cancer (HIPPoS Study)

Full title: Proof of mechanism study of an oral hedgehog inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period

Phase II Trial

Why is this trial being carried out?

This study is looking at the effect of a new study medication, GDC-0449, in patients with cancer of the pancreas that can be removed by surgery. The study medication has been developed by Roche-Genentech as an anti-cancer treatment. Laboratory studies have shown that this study medication blocks a form of chemical signalling between cells thought to be involved in the development and spread of pancreatic cancer. However it is not clear whether blocking this process affects the tumour itself or the surrounding normal tissue. Understanding this aspect will help scientists improve treatments for pancreatic cancer.

Who is the trial suitable for?

This trial may be suitable for patients, who have pancreatic cancer that can be removed by surgery, have undergone a diagnostic biopsy, and who can take GDC-0449 for 14 days before their operation. Your doctor(s) will explain these and any other requirements to join the trial.

Trial centre

Cambridge

Recruitment start date: February 2011

Recruitment end date: September 2012

For more information

ClinicalTrials.gov  or UK Clinical Research Network